1. Introduction
===============

Focal Adhesion Kinase (FAK) regulates many important cellular processes: proliferation, adhesion, spreading, motility, and survival \[[@B1-cancers-06-00166],[@B2-cancers-06-00166],[@B3-cancers-06-00166]\]. The previous study demonstrated that p53 bound FAK promoter and repressed FAK transcription \[[@B4-cancers-06-00166],[@B5-cancers-06-00166]\]. In addition, an analysis of 600 breast cancer tumors demonstrated that mutations of p53 highly correlated with FAK overexpression \[[@B6-cancers-06-00166],[@B7-cancers-06-00166]\]. Moreover, estradiol caused p53-dependent inhibition of FAK expression in breast cancer cells \[[@B8-cancers-06-00166]\]. These studies demonstrated the association of FAK and p53 signaling pathways in cancer \[[@B4-cancers-06-00166],[@B9-cancers-06-00166]\].

Recently we have demonstrated a direct interaction of p53 protein with the *N*-terminal domain of FAK \[[@B4-cancers-06-00166],[@B10-cancers-06-00166]\]. The interaction of FAK and p53 has been confirmed by another group, who demonstrated that FAK interacts not only with p53 but also with Mdm-2 to down-regulate p53 by ubiquitination \[[@B11-cancers-06-00166]\]. We identified the 7 amino-acid binding site (amino-acids 65-72) in the proline-rich region of p53 protein that is involved in interaction with FAK \[[@B12-cancers-06-00166]\] and by *in silico* modeling of NCI compound database we identified a small molecule compound Roslin 2 or R2 (1-benzyl-15,3,5,7-tetraazatricyclo\[3.3.1.1\~3,7\~\]decane) that directly bound to the *N*-terminal domain of FAK and disrupted FAK and p53 complex \[[@B13-cancers-06-00166]\]. The R2 compound decreased viability and colony formation of colon cancer cells in a p53-dependent manner, and reactivated transcriptional activity of p53 with p21, Mdm-2 and Bax transcriptional targets \[[@B13-cancers-06-00166]\]. In this report we performed microarray analysis with Illumina HumanRef-8 v3 bead chip on untreated HCTp53^+/+^ and HCTp53^−/−^ cells and on the cells treated with R2 compound and revealed \>1,484 genes significantly up- or down-regulated by R2 compound in a p53-dependent manner (*p* \< 0.05). Among these genes the known p53 pro-apoptotic targets, such as Mdm-2, Noxa-1, and RIP1, were detected. Moreover, the combination of R2 with either M13 disrupting FAK and Mdm-2, or with Nutlin-1 disrupting p53 and Mdm-2 interaction, decreased HCT116 cancer cell clonogenicity more efficiently than each inhibitor alone in a p53-dependent manner. Thus, this study revealed a gene expression profile in response to R2 and demonstrated that its combination with M13 or Nutlin-1 can be a novel therapy approach to reactivate p53 and decrease the survival of cancer cells.

2. Results
==========

2.1. Global Microarray Gene Profiling in HCT116 Cells Treated with R2 Demonstrated Up- and Down-Regulates Genes in a p53-Dependent Manner
-----------------------------------------------------------------------------------------------------------------------------------------

To detect global gene profiling and reveal differentially expressed genes in response to R2 compound that disrupted FAK and p53 interaction \[[@B13-cancers-06-00166]\], we performed a microarray analysis in R2-treated and untreated HCT116 p53^+/+^ and HCT116 p53^−/−^ cells using an Illumina Human ref-8 v3.0 bead chip and compared global gene expression ([Figure 1](#cancers-06-00166-f001){ref-type="fig"}). Since recently we detected that treatment of HCT116 cells at 25 μM of R2 for 24 hours significantly up-regulated transcriptional activity of p53, we treated HCT116 p53^+/+^ and HCT116p53^−/−^ cells with this dose of compound for 24 hours. The heatmap of the genes that are significantly up- or down-regulated, *p* \< 0.05 in untreated and R2-treated HCT116 p53^+/+^ and p53^−/−^ cells is shown in [Figure 1](#cancers-06-00166-f001){ref-type="fig"}. We detected 1,484 genes that were differentially expressed: down or up-regulated by 25 μM R2 treatment for 24 hours in HCT116 p53^+/+^ cells but not in HCT116 p53^−/−^ cells (*p* \< 0.05). The 961 genes were ≥1.2 fold significantly affected in HCT116p53^+/+^ cells, but not in HCTp53^−/−^ cells. The [Table 1](#cancers-06-00166-t001){ref-type="table"} presents a list of important genes ≥1.2 fold significantly up- or down-regulated in HCT116 p53^+/+^ cells (*p* \< 0.05), but not in HCT116 p53^−/−^ cells and also shows several genes that were significantly inversely affected in both cell lines (marked by an asterisk).

![Gene expression profiling in HCT116 p53^+/+^ and HCT116 p53^−/−^ cells in response to R2. The heatmap of untreated and R2-treated cells demonstrated significantly up-and down-regulated (*p* \< 0.05) genes in colon cancer cells. The heatmap is shown in the left panel. Red indicates significantly up-regulated genes, and green indicates down-regulated genes (*p* \< 0.05). Un-marks Untreated cells, R2 marks HCT116 cells treated with 25 μM R2 for 24 hours.](cancers-06-00166-g001){#cancers-06-00166-f001}

Among the genes up or down-regulated by R2 in a p53-dependent manner, we detected up-regulated targets of p53, such as Mdm-2 and Noxa1 and pro-apoptotic proteins RIP-1 ([Table 1](#cancers-06-00166-t001){ref-type="table"}). Among the down-regulated genes Met oncogene, PLK2, MTF1, KIF14, BIRC2 and other important genes were detected ([Table 1](#cancers-06-00166-t001){ref-type="table"}).

cancers-06-00166-t001_Table 1

###### 

Several up-regulated and down-regulated genes by 25 μM R2 in HCT116 p53^+/+^ cells in a p53-dependent manner (≥1.2-fold, *p* \< 0.05).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Up-regulated genes                                                                                                                                                                                                                                                                              
  -------------------------- --------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------- --------------- ------------------------------------------ ---------------
  **Entrez**\                **Gene Symbol**             **Name**                                                                **Function**                                                               **Fold Change**\           ***p*-value**   **Fold Change** **R2-treated/Untreated**   ***p*-value**
  **Gene ID**                                                                                                                                                                                               **R2-treated/Untreated**                                                              

  **8737**                   **RIPK1**                   **Receptor (TNFRSF)-interacting serine-threonine kinase 1**             **Apoptosis, regulation of I-kappa B/NF-kappa B cascade**                  **1.20**                   **0.01**        **0.95**                                   **0.46**

  3725                       JUN                         Jun oncogene Serine-threonine kinase 1                                  Transcription                                                              1.21                       0.07            1.01                                       0.83

  **10811**                  **NOXA1**                   **NADPH oxidase activator**                                             **Superoxide metabolic process**                                           **1.20**                   **0.01**        **0.85**                                   **0.02**

  8739                       HRK                         Harakiri, Bcl2 interacting protein                                      Induction of apoptosis                                                     1.22                       0.01            1.06                                       0.37

  **4193**                   **MDM2**                    **Mdm2 p53 binding protein homolog (mouse)**                            **Ubiquitination, negative regulation of proliferation**                   **1.22**                   **0.03**        **0.92**                                   **0.29**

  10608                      MXD4                        MAX dimerization protein 4                                              Negative regulation of transcription                                       1.23                       0.025           1.00                                       0.93

  5602                       MAPK13                      Mitogen-activated protein kinase 13                                     Protein phosphorylation                                                    1.23                       0.017           0.87                                       0.08

  3429                       IFI27                       Interferon inducible protein 27                                         Interferon-regulated process                                               1.25                       0.013           0.99                                       0.93

  5300                       PIN1                        Peptidylprolil cis/trans isomerase                                      Cell cycle, protein folding                                                1.26                       0.004           0.95                                       0.49

  **7159**                   **TP53BP2 \***              **Tumor p53 binding protein 2**                                         **Apoptosis**                                                              **1.28**                   **0.014**       **0.79**                                   **0.02**

  9064                       MAP3K6                      Mitogen-activated kinase-kinase 6                                       Protein phosphorylation                                                    1.28                       0.003           1.08                                       0.22

  1396                       CRIP1                       Cysteine-rich protein 1                                                 Cell proliferation                                                         1.31                       0.026           1.17                                       0.046

  7867                       MAPKAPK3                    Mitogen-activated protein kinase 3                                      Protein phosphorylation                                                    1.36                       0.0008          0.95                                       0.48

  3675                       ITGA3                       Integrin, alpha 3                                                       Cell adhesion                                                              1.40                       0.0003          1.1                                        0.13

  5296                       PIK3R2                      Phosphoinositide-3-kinase, regulatory subunit                           Signal transduction                                                        1.41                       0.00019         0.88                                       0.084

  83990                      BRIP1 \*                    BRCA1 interacting protein *C*-terminal helicase 1                       DNA damage checkpoijnt metabolic process                                   1.43                       0.0024          0.64                                       0.00056

  90850                      ZNF598                      Zinc finger protein 598                                                 Protein binding                                                            1.51                       0.0029          1.07                                       0.41

  3659                       IRF1                        Interferon regulatory factor 1                                          Regulation of interleukin-12                                               1.55                       9.04E-05        1.00                                       0.99

  85441                      PRIC285                     Peroxisomal proliferator-activated receptor A interacting complex 285   Regulation of transcription                                                1.58                       4.98E-05        0.83                                       0.028

  22937                      SCAP                        SREBF chaperone                                                         Lipid metabolic process                                                    1.61                       1.5E-0.5        0.96                                       0.51

  5652                       PRSS8                       Protease, serine, 8                                                     Proteolysis                                                                1.81                       2.21E-06        0.96                                       0.59

  147166                     TRIM16L \*                  Tripartite motif-containing 16-like                                                                                                                1.84                       0.008           0.47                                       0.0025

  **Down-regulated genes**                                                                                                                                                                                                                                                                        

                             **HCT116 p53^+/+^ cells**   **HCT116p53^−/−^ cells**                                                                                                                                                                                                                 

  **Entrez**\                **Gene Symbol**             **Name**                                                                **Function**                                                               **Fold Change**\           ***p*-value**   **Fold Change**\                           ***p*-value**
  **Gene ID**                                                                                                                                                                                               **R2-treated/Untreated**                   **R2-treated/Untreated**                   

  7272                       TTK \*                      TTK protein kinase                                                      Protein amino acid phosphorylation; Mitotic spindle organization           0.82                       0.016           1.2                                        0.02

  **10769**                  **PLK2**                    **Polo-like kinase 2**                                                  **Mitotic cell cycle**                                                     **0.82**                   **0.019**       **1.05**                                   **0.47**

  4233                       MET                         Met proto-oncogene                                                      Protein amino acid phosphorylation; Multicellular organismal development   0.81                       0.01            0.89                                       0.14

  **27085**                  **MTBP**                    **Mdm-2, transformed 3T3 cell double minute 2, p53 binding protein**    **Ubiquitin-dependent protein catabolic process; cell cycle**              **0.80**                   **0.0066**      **1.13**                                   **0.1**

  4436                       MSH2                        Mut S homolog 2                                                         Mismatch repair                                                            0.8                        0.017           0.88                                       0.13

  2353                       FOS                         FOS oncogene                                                            DNA methylation, transcription                                             0.77                       0.032           1.07                                       0.51

  64282                      PAPD5 \*                    PAP associated domain 5                                                 DNA replication; cell cycle                                                0.77                       0.028           1.77                                       0.0007

  9928                       KIF14                       Kinesin 14                                                              Microtubule-based movement                                                 0.76                       0.01            1.02                                       0.82

  9112                       MTA1                        Metastasis associated 1                                                 Regulation of transcription                                                0.75                       0.026           1.26                                       0.06

  7013                       TERF1 \*                    Telomeric repeat binding factor 1                                       Telomere maintenance via telomerase                                        0.74                       0.001           1.26                                       0.0058

  5099                       PCDH7                       Procadherin 7                                                           Cell adhesion                                                              0.73                       0.002           1.16                                       0.09

  4774                       NFIA                        Nuclear factor 1/A                                                      DNA replication; transcription                                             0.72                       0.008           1.23                                       0.06

  54434                      SSH1 \*                     Slingshot homolog 1                                                     Cell morphogenesis; cytoskeleton                                           0.65                       0.015           1.53                                       0.015

  329                        BIRC2                       Baculoviaral IAP repeat-containing 2                                    Cell surface receptor linked signaling pathway;\                           0.62                       1.43E-05        0.93                                       0.36
                                                                                                                                 regulation of apoptosis                                                                                                                                          

  4520                       MTF 1 \*                    Metal regulatory transcription factor 1                                 Regulation of transcription;\                                              0.58                       0.003           1.66                                       0.004
                                                                                                                                 Response to oxidative stress                                                                                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genes encoding p53 targeted proteins or proteins associated with p53 pathway are marked in bold. \* The significantly inversely affected genes in HCT116 p53^+/+^ and HCT116 p53^−/−^ marked with an asterisk.

Real-time PCR analysis confirmed and validated several up-regulated genes: RIP1, Mdm-2, PRSS8, and BRIP, and several down-regulated genes: MET, MTF1, PLK1, and BIRC2 ([Figure 2](#cancers-06-00166-f002){ref-type="fig"}). The data of RT-PCR and microarray analyses were very similar ([Figure 2](#cancers-06-00166-f002){ref-type="fig"}). Thus, R2 reactivated p53 activity and affected many p53 target and critical genes in a p53-dependent manner.

![Real-time confirmed and validated differentially expressed up- and down-regulated (*p* \< 0.05) genes in R2-treated cells *versus* untreated cells. The fold of RQ treated to untreated ratios is shown for RT-PCR. The bold black bars show average fold of ratios of R2 treated to untreated by microarray analysis and the striped black and white bars show average fold of mRNA levels of gene expression by RT-PCR analysis. Up-regulated and down-regulated genes are marked. The changes are statistically significant, *p* \< 0.05.](cancers-06-00166-g002){#cancers-06-00166-f002}

2.2. The R2 Sensitized Cancer Cells to M13 (Disrupting FAK and Mdm-2) and Nutlin-1 (Disrupting p53 and Mdm-2) Treatments
------------------------------------------------------------------------------------------------------------------------

Since we detected p53-dependent up-regulation of Mdm-2 expression ([Table 1](#cancers-06-00166-t001){ref-type="table"}) in HCT116p53^+/+^ cells, and Mdm-2 was shown to bind FAK to down-regulate p53, providing survival to cancer cells \[[@B11-cancers-06-00166]\], we used compound M13 that disrupted interaction of FAK and Mdm-2, called M13 that up-regulated p53 activity and caused apoptosis in HCT116 p53^+/+^ cells \[[@B14-cancers-06-00166]\] in combination with R2 in clonogenicity assay to test if combination of R2 and M13 will decrease cancer cell clonogenicity more effectively than each agent alone. [Figure 3](#cancers-06-00166-f003){ref-type="fig"}A shows that combination of R2 and M13 is more effective in decreasing clonogenicity of HCT116 p53^+/+^ cells than each agent alone. This effect was not observed in HCT116 p53^−/−^ cells.

Since Nutlin-1 that disrupts p53 and Mdm-2 protein interaction \[[@B15-cancers-06-00166]\], also can induce p53, we treated HCT116 p53^+/+^ and HCT53^−/−^ cells with either R2 alone, Nutlin-1 alone or with combination of R2 and Nutlin-1 ([Figure 1](#cancers-06-00166-f001){ref-type="fig"}B). The combination of R2 and Nutlin-1 also decreased number of colonies compared with each agent alone in HCT116 p53^+/+^ cells in a p53-dependent manner ([Figure 3](#cancers-06-00166-f003){ref-type="fig"}B). Thus, the combination of R2 and M13 or R2 and Nutlin-1 was more effective in decreasing clonogenicity than with each agent alone in HCTp53^+/+^ cells, but not in HCT116 p53^−/−^ cells ([Figure 3](#cancers-06-00166-f003){ref-type="fig"}).

![R2 sensitized HCT116 cells to M13 and Nutlin. Clonogenicity assay was performed on HCT116p53^+^/^+^ cells or HCT116p53^−^/^−^ treated for one week either with R2 alone, M13 alone, or with a combination of R2 and M13 (**A**), or R2 alone, Nutlin-1 alone, or with combination of R2 and Nutlin-1 (**B**). The representative clonogenicity assay of several independent experiments is shown. Colonies were counted and quantification is shown on the right panels. Bars show average number of colonies per treatment from two or four independent experiments. \* Student's t-test, *p* \< 0.05, R2+M13 or R2+Nutlin-1 *versus* untreated HCT116p53^+/+^ and HCT116 p53^−/−^ or treated cells with a single agent. The *p*-values are shown in combination group *versus* single agent.](cancers-06-00166-g003){#cancers-06-00166-f003}

Thus, a combination of compounds that target FAK and p53, FAK and Mdm-2 or p53 and Mdm-2 can be an effective therapeutic approach to block colon cancer cells.

3. Experimental
===============

3.1. Cell Lines and Culture
---------------------------

The early passage HCT116p53^−^/^−^ and HCT116p53^+^/^+^ colon cancer cells were obtained from Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA) and maintained in McCoy's5A medium with 10% FBS and 1 μg/mL penicillin/streptomycin. The cells were passaged less than two month after resuscitation of frozen aliquots.

3.2. Reagents
-------------

R2 (1-benzyl-15,3,5,7-tetraazatricyclo\[3.3.1.1\~3,7\~\]decane) was kindly provided by Drs. Ethirajan Manivannan and Ravindra Pandey (Roswell Park Cancer Institute, Buffalo, NY, USA). M13 (5\'-*O*-tritylthymidine) and Nutlin-1 were obtained from Sigma (St. Louis, MO, USA). The compounds were solubilized in DMSO at a concentration of 25 mM.

3.3. Clonogenicity Assay
------------------------

One thousand cells were plated on six-well plates and incubated with different R2 compound, M13, Nutlin-1 or with combination of R2 and M13 or R2 and Nutlin-1 compounds or without compound for seven or ten days. Then cells were fixed in 25% methanol and stained with Crystal Violet. The colonies were counted from two of four independent experiments per each treatment group.

3.4. RNA Isolation
------------------

The untreated and treated cells with 25 μM R2 for 24 hours were used for isolation of RNA. Total RNA was isolated from the frozen cell pellets using the RNeasy midi kits (Qiagen, Inc., Valencia, CA, USA) following the manufacturer's instructions. Before labeling, RNA samples were quantitated using a ND-1000 spectrophotometer (Nano Drop, Wilmington, DE, USA).

3.5. Microarray Analysis
------------------------

Expression profiling was accomplished using the HumanRef-8 whole-genome gene expression array and direct hybridization assay (Illumina, Inc., San Diego, CA, USA). Initially, 500 ng total RNA was converted to cDNA, followed by *in vitro* transcription to generate biotin labeled cRNA using the Ambion Illumina Total Prep RNA Amplification Kit (Ambion, Inc., Foster City, CA, USA) according to the manufacturer's instructions. The labeled probes were hybridized overnight at 58 °C to the Illumina HumanRef-8v3BeadChips. Following washing and staining with Cy3-streptavidin conjugate, the BeadChips were imaged using the Illumina Bead Array Reader to measure fluorescence intensity at each probe. The raw intensity of each Illumina Human ref-8 v3.0 gene expression array was scanned and extracted using Bead Scan, with the data corrected by background subtraction in Genome Studio (v2010.1), gene expression module (v1.6.0). The BeadChip data files were further analyzed with a *Bioconductor* package to determine gene expression signal levels.

3.6. Bioinformatics and Statistical Analyses
--------------------------------------------

The *lumi* module in the R-based *Bioconductor* package was used to transform the expression intensity to log2 scale. The log2 transformed intensity data were normalized using the Quantile normalization algorithm. The *Limma* program in the *Bioconductor* package under R computing environment was used to calculate the level of differential gene expression. Briefly, a linear model based on Bayesian method has been used to fit to the data (with cell means corresponding to the different conditions and a random effect for array). Each sample was analyzed in duplicate. For each comparison, we obtained the list of differentially expressed genes constrained by *p*-value \< 0.05 and at least 1.2 fold change. Microarray and bioinformatics analysis were submitted to NCBI and the GEO accession number is GSE33918.

3.7. Real-Time PCR
------------------

Real-time PCR with forward and reverse primers and fluorescent probe 5'FAM and 3'TAMRA was performed, as described in \[[@B6-cancers-06-00166]\]. The primers (marked f-for forward and r-for reverse) and fluorescent probes for microarray validation by RT-PCR were the following: RIP: f-5\'-ATATCCCAGTGCCTGAGACC-3\', r-5\'-AGATTCATCTGTTGGTGGCA-3\', and probe 5\'-CCCAC CATGCCATTCAGCTCC-3\'; Mdm-2: f-5\'GAATCTACAGGGACGCCATC3\', r-5\'-CTGATCCAAC CAATCACCTG-3\', and probe 5\'-TCACTTACACCAGCATCAAGATCCGG-3\'; PRSS8: f-5\'-ATG GTGTGTGCTGGCTATGT-3\', r-5\'-CGTCAGGTACCAGAGACCCT-3\', and probe 5\'-CGCCTGCC AGGGTGACTCTG-3\'; BRIP: f-5\'-CAGATGAGGGCGTAAGTGAA-3\', r-5\'-TCTTTCAGAAGGT GGTGTGC-3\', and probe 5\'-TCATGTTGTTGTGCATGCCATTCA-3\'; MET, f-5\'-CAGCGCGTTGA CTTATTCAT-3\', r-5\'-CCCTCTGATGTCCCAAGATT-3\' and probe 5\'-CCACCTTCATTAAAGG AGACCTCACCA-3\'; MTF, f-5\'-CAATGCACTTCCACAACACA-3\', r-5\'-CCTGGGTCGTACTG GAATTT-3\', and probe 5\'-TTCTGTCCACAGATTCTGAATTGCGA-3\'; PLK, f-5\'-GAGCAGCTG AGCACATCATT-3\', r-5\'-CATGTGAGCACCATTGTTGA-3\', and probe 5\'-CAGACCACACCGTC GGTGTCC-3\'; BIRC2, f-5\'-GCTAGTCTGGGATCCACCTC-3\', r-5\'-AGAGGGTTTGGAGAAAG GCT-3\', and probe 5\'-TGCACATTCATTATCTCCCACCTTGG-3\'. GAPDG was used as endogenous control, as described \[[@B6-cancers-06-00166]\]. All experiments were performed in triplicates and RQ was calculated for each gene tested.

3.8. Statistical Analyses
-------------------------

Student's t test was performed to determine significance. The difference between treated and untreated samples with *p* \< 0.05 was considered significant.

4. Discussion
=============

By microarray gene expression profiling analysis we identified differentially expressed genes in HCT116 p53^+^/^+^ cells affected by R2 in a p53-dependent manner. Among differentially expressed genes, important down-stream players of p53 signaling were identified, such as Mdm-2, Noxa-1, and RIP-1.

We detected 1484 genes that were up or down-regulated by R2 in HCT116p53^+/+^ cells but not in HCT116^−/−^ cells. Among these genes are Mdm-2, a known transcriptional target of p53 \[[@B16-cancers-06-00166]\]. And it has been shown also to be up-regulated by Nutlins, which disrupted binding of Mdm-2 and p53 as a result of p53 increased activity and expression \[[@B16-cancers-06-00166]\]. Among up-regulated genes, RIP-1 has been detected. In a previous report we demonstrated an association of FAK and RIP-1, where FAK sequestered pro-apoptotic RIP-1 from its pro-apoptotic functioning \[[@B17-cancers-06-00166]\]. Thus, activation of RIP-1 by R2 can decrease the survival functions of colon cancer cells. Another gene, encoding Noxa-1 protein (Phorbol-12-myristate-13-acetate-induced protein 1) was one of the significantly up-regulated targets caused by R2. It is known that Noxa-1 is a transcriptional target of p53 and is a pro-apoptotic member of the Bcl-2 proteins family and is involved in p53-mediated apoptotic signaling \[[@B18-cancers-06-00166]\].

Another up-regulated gene is BRIP1 (BRCA1-interacting protein 1) which encodes Fanconi anemia group J protein, a member of DNA helicase \[[@B19-cancers-06-00166]\], known to be critical for breast cancer suppression and DNA repair. BRIP1 protein is mutated in the cancer prone syndrome Fanconi anemia, a disorder characterized by congenital malformations and a predisposition to the development of malignancies. At the molecular level, it is associated with chromosomal instability and defective DNA repair.

PRSS8 gene was also significantly up-regulated by R2. It encodes serine protease 8 or prostasin, known as a suppressor of invasion. Recently, loss of prostasin has been shown to be associated with epithelial-mesenchymal transition (EMT) \[[@B20-cancers-06-00166]\].

Among down-regulated genes, Met gene encoding Met protooncogene has been detected. It is known that Met interacts with FAK and controls survival signaling in cancer cells \[[@B21-cancers-06-00166]\]. Thus, the microarray study confirmed our functional data on up-regulation of p53 targets by R2 and revealed novel genes and signaling pathways affected by FAK and p53 disruption.

Another protein encoded by PLK2 (Polo-like Kinase 2), one of the p53 targets \[[@B22-cancers-06-00166]\], was also affected by R2 \[[@B23-cancers-06-00166]\]. Recently, PLK-2 deficient tumors demonstrated increased apoptosis in response to chemotherapy and silencing of PLK2 also caused increased apoptosis due to mitotic catastrophe, suggesting that PLK functions in the cell cycle arrest \[[@B24-cancers-06-00166]\].

Among down-regulated proteins by R2 microarray analysis, we detected Mdm-2-binding protein, encoded by the MTBP gene. This protein has been shown to bind Mdm-2 \[[@B25-cancers-06-00166]\] and regulates Mdm-2-dependent p53 homeostasis.

It is known that FAK and p53 interact and also that Mdm-2 interacts with p53 and with FAK \[[@B11-cancers-06-00166]\]. Since, we detected increased Mdm-2 expression by R2, and Mdm-2 was shown to bind FAK and p53 to down-regulate p53 activity, we tested combination of drugs targeting of these complexes by combination of R2 and M13 or R2 and Nutlin-1. We demonstrated increased efficacy of the combinations in HCT116p53^+/+^ cells, but not HCTp53^−/−^ cells. Thus, the combination of therapies targeting FAK-p53 and FAK-Mdm-2 or FAK-p53 and Mdm-2-p53 can be important to enhance targeting of these complexes. Thus, Roslin 2 or R2 compound can be a potential approach for increasing p53 activity, similar to small molecule compounds such as Nutlins \[[@B16-cancers-06-00166]\] or RITA \[[@B26-cancers-06-00166]\] that are known to disrupt p53 and Mdm-2 interactions. The combination of FAK-p53 by R2 and FAK-Mdm-2 by M13 and Nutlin-1 targeting p53-Mdm-2 complexes can provide an effective combination therapy approach targeting the FAK scaffold \[[@B27-cancers-06-00166]\] that can be used in future preclinical and clinical trials.

5. Conclusions
==============

In conclusion, we demonstrated a gene expression profile in response to the small molecule compound R2 that targeted FAK and p53 interaction and showed that combination of FAK-p53-Mdm-2 targeting compounds that can be used as a novel approach *in vivo.* This study has a high impact on p53-regulated signaling and provides novel data on FAK and p53 interaction.
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